Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing Magnetic Microraft Technology for Single-Cell Isolation of CTCs from Whole Blood for scRNA-Seq Transcriptomic Characterization.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planus.

bioRxiv : the preprint server for biology·2026
Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors.

Nature reviews. Cancer·2025
Same author

Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.

International journal of molecular sciences·2025
Same author

Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes.

Journal for immunotherapy of cancer·2025

Related Experiment Video

Updated: Jun 26, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy.

Rosalyn M Fey1, Rebecca A Nichols1, Thuy T Tran2

  • 1Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.

Cancers
|May 11, 2024
PubMed
Summary

Macrophage migration inhibitory factor (MIF) and CD74 show promise as biomarkers to predict patient response to immune checkpoint blockade (ICB) therapy and the development of immune-related adverse events (irAEs). Further research is needed to validate their clinical utility.

Keywords:
CD74autoimmune diseasebiomarkerscancerimmune checkpoint blockade (ICB)immune-related adverse events (irAEs)macrophage migration inhibitory factor (MIF)

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

293

Related Experiment Videos

Last Updated: Jun 26, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

293

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint blockade (ICB) therapy is a cornerstone in cancer treatment but faces challenges with treatment resistance and immune-related adverse events (irAEs).
  • Identifying reliable predictive biomarkers for ICB response and toxicity is crucial for personalized cancer care.
  • Macrophage migration inhibitory factor (MIF) and its receptor CD74 are implicated in cancer progression and immune responses.

Purpose of the Study:

  • To evaluate the potential of MIF and CD74 as predictive biomarkers for ICB therapy response.
  • To assess their utility in predicting the development of irAEs.
  • To review existing evidence and suggest future research directions.

Main Methods:

  • Literature review of MIF and CD74 roles in cancer and autoimmune diseases.
  • Analysis of evidence supporting their potential as predictive biomarkers for ICB therapy and irAEs.
  • Consideration of factors affecting biomarker assessment, such as MIF's circadian expression.

Main Results:

  • MIF and CD74 have demonstrated associations with cancer progression and patient outcomes.
  • Emerging evidence suggests MIF and CD74 may predict response to ICB therapy.
  • These molecules also show potential in predicting irAE development.

Conclusions:

  • MIF and CD74 represent promising candidates for predictive biomarkers in ICB therapy.
  • Further research is warranted to establish their role in guiding treatment decisions and managing toxicity.
  • Understanding MIF's circadian rhythm is important for accurate biomarker interpretation.